Elsevier

Clinical Therapeutics

Volume 25, Issue 4, April 2003, Pages 1041-1055
Clinical Therapeutics

New drug
Olmesartan medoxomil: An angiotensin II-receptor blocker

https://doi.org/10.1016/S0149-2918(03)80066-8Get rights and content

Abstract

Background: Regulation of the activity of the renin-angiotensin-aldosterone system has become important in the management of cardiovascular disease. Olmesartan medoxomil (CS-866) is the newest selective angiotensin II-receptor blocker (ARB) to be approved for the treatment of hypertension.

Objective: This review describes the mechanism of action, pharmacokinetics, adverse-effect profile, drug-interaction potential, and dosing of olmesartan medoxomil. The results of relevant clinical efficacy and safety trials are also discussed.

Methods: This review is based on data from published clinical efficacy and safety trials and abstracts of conference presentations. To identify appropriate English-language publications for review, MEDLINE (1966–October 2002) and EMBASE (1990–2002) were searched using the terms olmesartan medoxomil, CS-866, angiotensin II-receptor blocker, and hypertension.

Results: Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension. Its blood pressure-lowering effects were comparable to those of other antihypertensive agents and other ARBs. Effects were seen as early as 2 weeks and persisted when olmesartan medoxomil was administered long term (for 1 year). The maximum recommended daily dose is 40 mg, except in the presence of severe renal insufficiency (creatinine clearance <20 mL/min) or moderate hepatic insufficiency (Child-Pugh score 7–9), when the daily dose should not exceed 20 mg. Olmesartan medoxomil was well tolerated. The most commonly reported adverse effect occurring significantly more often with olmesartan medoxomil than with placebo was dizziness (seen in ∼3% of patients). The occurrence of clinically significant drug interactions was minimal.

Conclusions: Based on the available literature, olmesartan medoxomil is an effective ARB for the treatment of hypertension, with a favorable adverse-effect and drug-interaction profile.

References (40)

  • E.J. Lewis et al.

    The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

    N Engl J Med

    (1993)
  • E.J. Lewis et al.

    Renoprotective effect

    N Engl J Med

    (2001)
  • B.M. Brenner et al.

    Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

    N Engl J Med

    (2001)
  • H.H. Parving et al.

    The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

    N Engl J Med

    (2001)
  • E.K. Jackson

    Renin and angiotensin

  • A.C. Guyton et al.

    Dominant role of the kidney in long-term regulation of arterial pressure and in hypertension: The integrated system for pressure control

  • E. Grossman et al.

    Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors?

    Arch Intern Med

    (2000)
  • H. Koike et al.

    In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist

    J Hypertens Suppl

    (2001)
  • H.R. Brunner

    The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview

    J Hum Hypertens

    (2002)
  • R. Toto

    Angiotensin II subytpe 1 receptor blockers and renal function

    Arch Intern Med

    (2001)

    • Cited by (0)

    View full text
    Copyright © 2003 Published by Elsevier Inc.